Preliminary Study of Buprenorphine and Bupropion for Opioid-Dependent Smokers

REFERENCES

• Kalman D, Morissette S B, George T P. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict. 2005; 14: 106–123
   PubMed Web of Science ®Google Scholar
• McCool R M, Richter K P, Choi W S. Benefits of and barriers to providing smoking treatment in methadone clinics: Findings from a national study. Am J Addict. 2005; 14: 358–366
   PubMed Web of Science ®Google Scholar
• Pomerleau O F. Endogenous opioids and smoking: A review of progress and problems. Psychoneuroendocrinology. 1998; 23: 115–130
   Google Scholar
• Mello N K, Lukas S E, Mendelson J H. Buprenorphine effects on cigarette smoking. Psychopharmacology (Berl). 1985; 86: 417–425
   PubMed Web of Science ®Google Scholar
• Mello N K, Mendelson J H, Sellers M L, Kuehnle J C. Effects of heroin self-administration on cigarette smoking. Psychopharmacology (Berl). 1980; 67: 45–52
   PubMed Web of Science ®Google Scholar
• Richter K P, Hamilton A K, Hall S, Catley D, Cox L S, Grobe J. Patterns of smoking and methadone dose in drug treatment patients. Exp Clin Psychopharmacol. 2007; 15: 144–153
   PubMed Web of Science ®Google Scholar
• Schmitz J M, Grabowski J, Rhoades H. The effects of high and low doses of methadone on cigarette smoking. Drug Alcohol Depend. 1994; 34: 237–242
   PubMed Web of Science ®Google Scholar
• Story J, Stark M J. Treating cigarette smoking in methadone maintenance clients. J Psychoactive Drugs. 1991; 23: 203–215
   PubMed Web of Science ®Google Scholar
• Spiga R, Schmitz J, Day J, II. Effects of nicotine on methadone self-administration in humans. Drug Alcohol Depend. 1998; 50: 157–165
   PubMed Web of Science ®Google Scholar
• Gilbert D G, Meliska C J, Williams C L, Jensen R A. Subjective correlates of cigarette-smoking-induced elevations of peripheral beta-endorphin and cortisol. Psychopharmacology (Berl). 1992; 106: 275–281
   PubMed Web of Science ®Google Scholar
• Meliska C J, Gilbert D G. Hormonal and subjective effects of smoking the first five cigarettes of the day: A comparison in males and females. Pharmacol Biochem Behav. 1991; 40: 229–235
   Google Scholar
• Pomerleau O F, Fertig J B, Seyler L E, Jaffe J. Neuroendocrine reactivity to nicotine in smokers. Psychopharmacology (Berl). 1983; 81: 61–67
   PubMed Web of Science ®Google Scholar
• Seyler L E, Jr., Pomerleau O F, Fertig J B, Hunt D, Parker K. Pituitary hormone response to cigarette smoking. Pharmacol Biochem Behav. 1986; 24: 159–162
   PubMedGoogle Scholar
• Stein M D, Weinstock M C, Herman D S, Anderson B J, Anthony J L, Niaura R. A smoking cessation intervention for the methadone-maintained. Addiction. 2006; 101: 599–607
   PubMed Web of Science ®Google Scholar
• Richter K P, McCool R M, Catley D, Hall M, Ahluwalia J S. Dual pharmacotherapy and motivational interviewing for tobacco dependence among drug treatment patients. J Addict Dis. 2005; 24: 79–90
   Google Scholar
• Shoptaw S, Rotheram-Fuller E, Yang X, et al. Smoking cessation in methadone maintenance. Addiction. 2002; 97: 1317–1328
   PubMed Web of Science ®Google Scholar
• Shoptaw S, Jarvik M E, Ling W, Rawson R A. Contingency management for tobacco smoking in methadone-maintained opiate addicts. Addict Behav. 1996; 21: 409–412
   PubMed Web of Science ®Google Scholar
• Boothby L A, Doering P L. Buprenorphine for the treatment of opioid dependence. Am J Health Syst Pharm. 2007; 64: 266–272
   PubMed Web of Science ®Google Scholar
• Mattick R P, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2003, CD002207
   Google Scholar
• Margolin A, Kosten T R, Avants S K, et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend. 1995; 40: 125–131
   PubMed Web of Science ®Google Scholar
• Margolin A, Kosten T, Petrakis I, Avants S K, Kosten T. Bupropion reduces cocaine abuse in methadone-maintained patients. Arch Gen Psychiatry. 1991; 48: 87
   PubMed Web of Science ®Google Scholar
• Poling J, Oliveto A, Petry N, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry. 2006; 63: 219–228
   PubMed Web of Science ®Google Scholar
• Poling J, Pruzinsky R, Kosten T R, et al. Clinical efficacy of citalopram alone or augmented with bupropion in methadone-stabilized patients. Am J Addict. 2007; 16: 187–194
   PubMed Web of Science ®Google Scholar
• Carroll K M, Kosten T R, Rounsaville B J. Choosing a behavioral therapy platform for pharmacotherapy of substance users. Drug Alcohol Depend. 2004; 75: 123–134
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Association, Washington, DC 1994
   Google Scholar
• First M B, Spitzer R L, Gibbon M, Williams J B. Structured Clinical Interview for DSM-IV Axis I Disorders—Patient Edition. Biometric Research Department, New York 1995, (SCID-I / P, Version 2.0)
   Google Scholar
• McLellan A T, Kushner H, Metzger D, et al. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992; 9: 199–213
   PubMed Web of Science ®Google Scholar
• Heatherton T F, Kozlowski L T, Frecker R C, Fagerstrom K O. The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction 1991; 86: 1119–1127
   PubMedGoogle Scholar
• Aickin M. A program for balancing the allocation of subjects to treatment in a clinical trial. Computers and Biomedical Research, an International Journal 1982; 15: 519–524
   Google Scholar
• Benowitz N L, Jacob P, Ahijevych K, et al. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002; 4: 149–159
   PubMedGoogle Scholar
• Hughes J R, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986; 43: 289–294
   PubMed Web of Science ®Google Scholar
• Bradley B P, Gossop M, Phillips G T, Legarda J J. The development of an opiate withdrawal scale (OWS). British Journal of Addiction 1987; 82: 1139–1142
   PubMedGoogle Scholar
• The SAS System for Windows [computer program]. Version 9.13. SAS Institute Inc., Cary, NC 2006
   Google Scholar
• Javors M A, Hatch J P, Lamb R J. Cut-off levels for breath carbon monoxide as a marker for cigarette smoking. Addiction. 2005; 100: 159–167
   PubMed Web of Science ®Google Scholar
• Aubin H J. Tolerability and safety of sustained-release bupropion in the management of smoking cessation. Drugs. 2002; 62(Suppl. 2)45–52
   PubMed Web of Science ®Google Scholar
• Stein M D, Anderson B J, Niaura R. Nicotine replacement therapy—patterns of use after a quit attempt among methadone-maintained smokers. J Gen Intern Med. 2006; 21: 753–757
   Google Scholar
• Peirce J M, Petry N M, Stitzer M L, et al. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: A National Drug Abuse Treatment Clinical Trials Network study. Arch Gen Psychiatry. 2006; 63: 201–208
   PubMed Web of Science ®Google Scholar
• Richter K P. Good and bad times for treating cigarette smoking in drug treatment. J Psychoactive Drugs. 2006; 38: 311–315
   PubMed Web of Science ®Google Scholar
• Hurt R D, Sachs D P, Glover E D, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997; 337: 1195–1202
   PubMed Web of Science ®Google Scholar